Given the outcomes of our screening strategy, we recommend that all patients referred for fragile-X (after confirming a normal karyotype), particularly those with a priori nonsyndromic ID or XLID, but also including cases with isolated cognitive impairment, be routinely screened for exon 2 size variants in ARX. Here, ARX is linked to Cognitive impairment.